• Je něco špatně v tomto záznamu ?

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study

HC. Lee, K. Ramasamy, M. Macro, FE. Davies, R. Abonour, F. van Rhee, VTM. Hungria, N. Puig, K. Ren, J. Silar, V. Enwemadu, D. Cherepanov, X. Leleu

. 2024 ; 113 (2) : 190-200. [pub] 20240423

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019594

Grantová podpora
Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA

OBJECTIVES: To characterize the impact of prior exposure and refractoriness to lenalidomide or proteasome inhibitors (PIs) on the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM). METHODS: INSURE is a pooled analysis of adult RRMM patients who had received IRd in ≥2 line of therapy from three studies: INSIGHT MM, UVEA-IXA, and REMIX. RESULTS: Overall, 391/100/68 were lenalidomide-naïve/-exposed/-refractory and 37/411/110 were PI-naïve/-exposed/-refractory. Median duration of therapy (DOT) was 15.3/15.6/4.7 months and median progression-free survival (PFS) was 21.6/25.8/5.6 months in lenalidomide-naïve/exposed/refractory patients. Median DOT and PFS in PI-naïve/exposed/refractory patients were 20.4/15.2/6.9 months and not reached/19.8/11.4 months, respectively. The proportion of lenalidomide-naïve/exposed/refractory patients in INSIGHT and UVEA-IXA who discontinued a study drug due to adverse events (AEs) was ixazomib, 31.6/28.2/28.0% and 18.6/6.7/10.5%; lenalidomide, 21.9/28.2/16.0% and 16.1/6.7/10.5%; dexamethasone, 18.4/20.5/16.0% and 10.6/0/10.5%, respectively. The proportion of PI-naïve/exposed/refractory patients in INSIGHT and UVEA-IXA who discontinued a study drug due to AEs was: ixazomib, 44.4/28.8/27.8% and 22.2/16.7/15.7%; lenalidomide, 33.3/22.0/19.4% and 16.7/15.9/11.8%; dexamethasone, 33.3/17.4/16.7% and 16.7/9.5/7.8%, respectively. REMIX AE discontinuation rates were unavailable. CONCLUSION: IRd appeared to be effective in RRMM patients in routine clinical practice regardless of prior lenalidomide or PI exposure, with better outcomes seen in lenalidomide- and/or PI-nonrefractory versus refractory patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019594
003      
CZ-PrNML
005      
20241024110616.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/ejh.14214 $2 doi
035    __
$a (PubMed)38654611
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Lee, Hans C $u Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA $1 https://orcid.org/0000000185453292
245    10
$a Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study / $c HC. Lee, K. Ramasamy, M. Macro, FE. Davies, R. Abonour, F. van Rhee, VTM. Hungria, N. Puig, K. Ren, J. Silar, V. Enwemadu, D. Cherepanov, X. Leleu
520    9_
$a OBJECTIVES: To characterize the impact of prior exposure and refractoriness to lenalidomide or proteasome inhibitors (PIs) on the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM). METHODS: INSURE is a pooled analysis of adult RRMM patients who had received IRd in ≥2 line of therapy from three studies: INSIGHT MM, UVEA-IXA, and REMIX. RESULTS: Overall, 391/100/68 were lenalidomide-naïve/-exposed/-refractory and 37/411/110 were PI-naïve/-exposed/-refractory. Median duration of therapy (DOT) was 15.3/15.6/4.7 months and median progression-free survival (PFS) was 21.6/25.8/5.6 months in lenalidomide-naïve/exposed/refractory patients. Median DOT and PFS in PI-naïve/exposed/refractory patients were 20.4/15.2/6.9 months and not reached/19.8/11.4 months, respectively. The proportion of lenalidomide-naïve/exposed/refractory patients in INSIGHT and UVEA-IXA who discontinued a study drug due to adverse events (AEs) was ixazomib, 31.6/28.2/28.0% and 18.6/6.7/10.5%; lenalidomide, 21.9/28.2/16.0% and 16.1/6.7/10.5%; dexamethasone, 18.4/20.5/16.0% and 10.6/0/10.5%, respectively. The proportion of PI-naïve/exposed/refractory patients in INSIGHT and UVEA-IXA who discontinued a study drug due to AEs was: ixazomib, 44.4/28.8/27.8% and 22.2/16.7/15.7%; lenalidomide, 33.3/22.0/19.4% and 16.7/15.9/11.8%; dexamethasone, 33.3/17.4/16.7% and 16.7/9.5/7.8%, respectively. REMIX AE discontinuation rates were unavailable. CONCLUSION: IRd appeared to be effective in RRMM patients in routine clinical practice regardless of prior lenalidomide or PI exposure, with better outcomes seen in lenalidomide- and/or PI-nonrefractory versus refractory patients.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x farmakoterapie $x mortalita $x diagnóza $7 D009101
650    12
$a sloučeniny boru $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D001896
650    12
$a glycin $x analogy a deriváty $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D005998
650    12
$a lenalidomid $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000077269
650    12
$a dexamethason $x aplikace a dávkování $x škodlivé účinky $7 D003907
650    12
$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $x aplikace a dávkování $7 D000971
650    _2
$a mužské pohlaví $7 D008297
650    12
$a inhibitory proteasomu $x aplikace a dávkování $x terapeutické užití $x škodlivé účinky $7 D061988
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    12
$a chemorezistence $7 D019008
650    _2
$a výsledek terapie $7 D016896
650    _2
$a dospělí $7 D000328
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a recidiva $7 D012008
650    _2
$a opakovaná terapie $7 D019233
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ramasamy, Karthik $u Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK $1 https://orcid.org/0000000333853707
700    1_
$a Macro, Margaret $u CHU de Caen Normandie, Caen, France
700    1_
$a Davies, Faith E $u Perlmutter Cancer Center, NYU Langone, New York City, New York, USA
700    1_
$a Abonour, Rafat $u Indiana University School of Medicine, Indianapolis, Indiana, USA
700    1_
$a van Rhee, Frits $u University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, USA
700    1_
$a Hungria, Vania T M $u Clinica São Germano and Santa Casa Medical School, São Paulo, Brazil
700    1_
$a Puig, Noemi $u Hematology Department, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
700    1_
$a Ren, Kaili $u Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA
700    1_
$a Silar, Jiri $u Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic
700    1_
$a Enwemadu, Victoria $u Takeda Pharmaceuticals U.S.A., Inc., Lexington, Massachusetts, USA
700    1_
$a Cherepanov, Dasha $u Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA
700    1_
$a Leleu, Xavier $u Pôle Régional de Cancérologie, Department of Hematology, CHU La Milétrie-Poitiers, Poitiers, France
773    0_
$w MED00001620 $t European journal of haematology $x 1600-0609 $g Roč. 113, č. 2 (2024), s. 190-200
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38654611 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110611 $b ABA008
999    __
$a ok $b bmc $g 2202058 $s 1231567
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 113 $c 2 $d 190-200 $e 20240423 $i 1600-0609 $m European journal of haematology $n Eur J Haematol $x MED00001620
GRA    __
$p Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace